Moreover, FABP3 has been defined as an independent predictor of CV events, including CV death, in subjects with suspected ACS [44], patients with HF and preserved ejection Fraction (HFpEF) [45] and in subjects with stable coronary artery disease and impaired glucose metabolism [48]. Here, FABP3 is linked to coronary artery disorder.